Grete B. Kro

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Epstein-Barr virus infection monitoring in kidney transplant recipients (EVITA study)-investigating the clinical significance of EBV-DNAemia and the risk of early-onset PTLD.

Epstein-Barr virus infection monitoring in kidney transplant recipients (EVITA study)-investigating the clinical significance of EBV-DNAemia and the risk of early-onset PTLD.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: December 17, 2025

Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab.

Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab.

Journal: BMJ neurology open

Published: December 01, 2025

Case Report: Donor-derived herpes simplex virus type 1 hepatitis in a kidney transplant recipient with fatal outcome.

Case Report: Donor-derived herpes simplex virus type 1 hepatitis in a kidney transplant recipient with fatal outcome.

Journal: Frontiers in transplantation

Published: March 11, 2025

Risk and prognosis of posttransplant lymphoproliferative disease in Epstein-Barr virus-seronegative kidney transplant recipients - an observational cohort study from Norway and western Denmark.

Risk and prognosis of posttransplant lymphoproliferative disease in Epstein-Barr virus-seronegative kidney transplant recipients - an observational cohort study from Norway and western Denmark.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: August 24, 2024

Cellular immunity against cytomegalovirus and risk of infection after kidney transplantation.

Cellular immunity against cytomegalovirus and risk of infection after kidney transplantation.

Journal: Frontiers in immunology

Published: April 09, 2024

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study.

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study.

Journal: RMD open

Published: July 28, 2023

Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants.

Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants.

Journal: NPJ vaccines

Published: January 25, 2023

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study.

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study.

Journal: The Lancet. Rheumatology

Published: November 23, 2022

Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants.

Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants.

Journal: NPJ vaccines

Published: July 12, 2022

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy.

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy.

Journal: RMD open

Published: April 19, 2022

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.

Journal: BMC medicine

Published: February 11, 2022

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.

Journal: The Lancet. Rheumatology

Published: January 03, 2022

Showing 1-12 of 17

Last Updated: 09/26/2026